XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF CASH AND CASH EQUIVALENTS AND INVESTMENTS (Details) - USD ($)
9 Months Ended 12 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Impairment Effects on Earnings Per Share [Line Items]      
Cash and Cash Equivalents $ 6,048,001 $ 16,249,666 $ 18,043,040
Cash [Member]      
Impairment Effects on Earnings Per Share [Line Items]      
Cost 1,370,129 1,233,608  
Cash and Cash Equivalents 1,370,129 1,233,608  
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]      
Impairment Effects on Earnings Per Share [Line Items]      
Cost 4,677,872 15,016,058  
Cash and Cash Equivalents 4,677,872 15,016,058  
Fair Value 4,677,872 15,016,058  
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]      
Impairment Effects on Earnings Per Share [Line Items]      
Cost 6,048,001 16,249,666  
Cash and Cash Equivalents 6,048,001 16,249,666  
Fair Value 4,677,872 15,016,058  
Investments [Member] | Fair Value, Inputs, Level 1 [Member]      
Impairment Effects on Earnings Per Share [Line Items]      
Cost 250,892 245,187  
Fair Value 247,511 239,314  
Unrealized Gain (Loss) (3,381) (5,873)  
Investments $ 247,511 $ 239,314